JP2024503441A5 - - Google Patents

Info

Publication number
JP2024503441A5
JP2024503441A5 JP2023542581A JP2023542581A JP2024503441A5 JP 2024503441 A5 JP2024503441 A5 JP 2024503441A5 JP 2023542581 A JP2023542581 A JP 2023542581A JP 2023542581 A JP2023542581 A JP 2023542581A JP 2024503441 A5 JP2024503441 A5 JP 2024503441A5
Authority
JP
Japan
Prior art keywords
independently
optionally substituted
cells
subject
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503441A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012954 external-priority patent/WO2022159475A1/en
Publication of JP2024503441A publication Critical patent/JP2024503441A/ja
Publication of JP2024503441A5 publication Critical patent/JP2024503441A5/ja
Pending legal-status Critical Current

Links

JP2023542581A 2021-01-20 2022-01-19 イオン化可能な脂質を含むナノ材料 Pending JP2024503441A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163139732P 2021-01-20 2021-01-20
US63/139,732 2021-01-20
PCT/US2022/012954 WO2022159475A1 (en) 2021-01-20 2022-01-19 Nanomaterials comprising an ionizable lipid

Publications (2)

Publication Number Publication Date
JP2024503441A JP2024503441A (ja) 2024-01-25
JP2024503441A5 true JP2024503441A5 (cg-RX-API-DMAC10.html) 2025-01-28

Family

ID=82549746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542581A Pending JP2024503441A (ja) 2021-01-20 2022-01-19 イオン化可能な脂質を含むナノ材料

Country Status (7)

Country Link
US (1) US20240115511A1 (cg-RX-API-DMAC10.html)
EP (1) EP4281064A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024503441A (cg-RX-API-DMAC10.html)
CN (1) CN116963729A (cg-RX-API-DMAC10.html)
AU (1) AU2022210317A1 (cg-RX-API-DMAC10.html)
CA (1) CA3203741A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022159475A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600208B2 (ja) 2019-07-29 2024-12-16 ジョージア テック リサーチ コーポレイション 拘束された脂質を含むナノ材料およびその使用
CN115175894B (zh) 2020-01-09 2024-09-06 盖德治疗有限责任公司 纳米材料
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
EP4281080A4 (en) 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
CN116761888A (zh) 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2024238658A2 (en) * 2023-05-15 2024-11-21 The Trustees Of The University Of Pennsylvania Delivery vehicle for targeted delivery to cardiomyocytes
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AU2024408317A1 (en) * 2023-12-18 2026-06-11 Lifemine Therapeutics, Inc. Triester compounds and methods of use thereof
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026142951A1 (en) 2024-12-23 2026-07-02 Genzyme Corporation Pharmaceutical system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
JP2012505855A (ja) * 2008-10-17 2012-03-08 ユニヴェルシテ リブレ ド ブリュッセル 抗癌治療における使用のためのジバニロイルおよびトリバニロイル誘導体
ES2887254T3 (es) * 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
BR112019025104A2 (pt) * 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
KR102710962B1 (ko) * 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
CN116761888A (zh) * 2021-01-20 2023-09-15 比姆医疗股份有限公司 纳米材料

Similar Documents

Publication Publication Date Title
JP2024505449A5 (cg-RX-API-DMAC10.html)
JP2024502948A5 (cg-RX-API-DMAC10.html)
JP2025501731A5 (cg-RX-API-DMAC10.html)
JP2024508347A5 (cg-RX-API-DMAC10.html)
JP2024502954A5 (cg-RX-API-DMAC10.html)
JP7654724B2 (ja) 治療剤の細胞内送達のための化合物および組成物
JP2025500824A5 (cg-RX-API-DMAC10.html)
RU2175337C2 (ru) Полинуклеотидные композиции
CA3113436A1 (en) Compounds and compositions for intracellular delivery of therapeutic agents
CN119684140A (zh) 纳米材料
CN120423969A (zh) 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
WO2022168085A1 (en) Lipids suitable for nucleic acid delivery
EP3661563A1 (en) Biomimetic nanomaterials and uses thereof
KR20120046099A (ko) 섬유화를 억제하고 섬유화 질병을 치료하는 방법
WO2017190145A1 (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US6344576B1 (en) Phospholipid-analogous compounds
Mancino et al. RNA therapies for musculoskeletal conditions
EP4603475A1 (en) Amino lipid compound and lipid nanoparticle for delivering bioactive ingredient
US8501680B2 (en) Antagonists against interaction of PF4 and RANTES
EP0652755B1 (en) Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine
FR3110836A1 (fr) Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
CN121729406A (zh) 具有提高的稳定性的可生物降解的氨基甲酸酯脂质
JP2025540229A (ja) 複数の第三級アミン構造を含むビスホスホリルアミド化合物、及びその組成物と使用
JP7842738B2 (ja) バイオインスパイアード脂質誘導体及びその使用
JP5638958B2 (ja) ウイルス性肝炎におけるsLDLR